28 dage under vedligeholdelsesfasen i forhold til basislinien (- 35, 8% med Inovelon vs. - 1, 6% med placebo, p=0, 0006), antallet af toniske- atonsike anfald (- 42. 9% med Inovelon vs.
A significant improvement was observed for all three primary variables: the percentage change in total seizure frequency per 28 days during the maintenance phase relative to baseline (-35.8% on Inovelon vs. – 1.6% on placebo, p= 0.0006), the number of tonic-atonic seizures (-42.9% on Inovelon vs.